美国阿片危机中的多物质使用
该综述指出美国阿片危机涉及多种物质,仅针对阿片的干预可能限制其解决多物质使用问题的能力。阿片与其他物质的重叠使用范围广泛,且多物质使用增加发病率和死亡率。需要在预防、治疗、过量逆转、公共卫生监测和研究各环节应对阿片与多种物质的重叠使用。
要点
- 阿片危机包含多种物质,仅针对阿片的干预可能无法解决多物质使用问题。
- 非医疗阿片使用者常使用其他药物,多物质使用增加发病率和死亡率。
- 需在预防、治疗、过量逆转、监测和研究各环节应对多物质使用。
核心结论
- 解决阿片与多种其他物质的重叠使用,对于在预防和治疗干预、过量逆转、公共卫生监测和研究全谱系中实现最大效益是必要的。
主要发现
- 阿片与其他物质的重叠范围从整个生命周期中使用的物质转变到同时共用跨越相似和不同药理学类别的物质。
- 证据表明非医疗阿片使用者相当常见地使用其他药物,且这种多物质使用导致发病率和死亡率增加。
- 在阿片中添加其他物质的原因包括增强快感(相加或协同奖励)、通过服用另一种药物补偿一种药物的不良效应、补偿负面内状态,或与所有物质消费相关的共同易感性。
- 但多种物质的消费本身可能具有独特效应。
临床怎么用
- 通过应对多种消费模式以及人们将阿片与其他物质混合的原因,干预和研究可能得到增强。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interventions to address the U.S. opioid crisis primarily target opioid use, misuse, and addiction, but because the opioid crisis includes multiple substances, the opioid specificity of interventions may limit their ability to address the broader problem of polysubstance use. Overlap of opioids with other substances ranges from shifts among the substances used across the lifespan to simultaneous co-use of substances that span similar and disparate pharmacological categories. Evidence suggests that nonmedical opioid users quite commonly use other drugs, and this polysubstance use contributes to increasing morbidity and mortality. Reasons for adding other substances to opioids include enhancement of the high (additive or synergistic reward), compensation for undesired effects of one drug by taking another, compensation for negative internal states, or a common predisposition that is related to all substance consumption. But consumption of multiple substances may itself have unique effects. To achieve the maximum benefit, addressing the overlap of opioids with multiple other substances is needed across the spectrum of prevention and treatment interventions, overdose reversal, public health surveillance, and research. By addressing the multiple patterns of consumption and the reasons that people mix opioids with other substances, interventions and research may be enhanced.
引用
- Compton WM, Valentino RJ, DuPont RL, et al. Polysubstance use in the U.S. opioid crisis. Mol Psychiatry. 2020. PMID: 33188253. doi:10.1038/s41380-020-00949-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。